Combining imaging and genetic information to predict disease presence and behavior is being codified into an emerging discipline called "radiogenomics." Optimal evaluation methodologies for radiogenomics techniques have not been established. We aim to develop a clinical decision framework based on utility analysis to assess prediction models for breast cancer. Our data comes from a retrospective case-control study, collecting Gail model risk factors, genetic variants (single nucleotide polymorphisms-SNPs), and mammographic features in Breast Imaging Reporting and Data System (BI-RADS) lexicon. We first constructed three logistic regression models built on different sets of predictive features: (1) Gail, (2) Gail+SNP, and (3) Gail+SNP+BI-RADS. Then, we generated ROC curves for three models. After we assigned utility values for each category of findings (true negative, false positive, false negative and true positive), we pursued optimal operating points on ROC curves to achieve maximum expected utility (MEU) of breast cancer diagnosis. We used McNemar's test to compare the predictive performance of the three models. We found that SNPs and BI-RADS features augmented the baseline Gail model in terms of the area under ROC curve (AUC) and MEU. SNPs improved sensitivity of the Gail model (0.276 vs. 0.147) and reduced specificity (0.855 vs. 0.912). When additional mammographic features were added, sensitivity increased to 0.457 and specificity to 0.872. SNPs and mammographic features played a significant role in breast cancer risk estimation (p-value < 0.001). Our decision framework comprising utility analysis and McNemar's test provides a novel framework to evaluate prediction models in the realm of radiogenomics.
INTRODUCTION
Effective clinical decision making about screening, diagnosis, surgery, and preventive intervention for cancer relies on accurate assessment of a patient's cancer risk, which has prompted the development of a number of cancer risk prediction models [1] [2] [3] [4] [5] [6] [7] [8] [9] . The "Breast Cancer Risk Assessment Tool" (the Gail model) is a prominent risk prediction model based on self-reported demographic risk factors including age, age at menarche, age at first live birth, the number of first-degree relatives with a diagnosis of breast cancer, and number of previous breast biopsies 2 , which has limited discriminatory power.
Recent advances in genome-wide association studies (GWAS) and successes with cost reduction in genomesequencing have paved the road for developing prediction models to potentially estimate breast cancer risk on the basis of both demographic risk factors and genetic variants. However, early attempts to use genetic variants to predict breast cancer risk have demonstrated only modest improvements over conventional demographic risk factors 2, 8, 10 . On the other hand, there is a long history of risk estimation for breast cancer by using imaging findings garnered from mammograms [11] [12] [13] [14] . However, it has proven a difficult task to characterize the molecular properties of malignancies using imaging findings. Now it is widely agreed that imaging findings, in concert with genetic variants will likely be necessary for accurate assessment of a patient's cancer risk. A promising new paradigm, radiogenomics delves into the analysis of the interaction of imaging findings, genetic variants, and cancer risk [15] [16] [17] [18] .
The performance of prediction models in radiogenomics has typically been evaluated with the area under the receiver operating characteristic (ROC) curve (AUC) 15 . Although AUC is a popular statistical measure, the technique has several weaknesses [19] [20] [21] . AUC does not account for the prevalence of disease or the consequence of decisions, which heavily influences the ultimate outcomes of medical decisions. AUC considers the entire ROC curve while in reality just a single threshold point matters in decision making. A radiologist consciously or subconsciously chooses one threshold point of sensitivity/specificity for recommending further management. Of note, prior studies demonstrate that the increment of AUC was only moderate when some genetic variants that were strongly associated with breast cancer were added to models possessing reasonable good discrimination 3, 22, 23 .
Expected utility (EU) analysis is a fundamentally complementary component of ROC analysis, which explicitly considers the clinical consequences of decisions by summing the utility of each possible outcome (true positive, false positive, true negative, and false negative) weighted by the probability of that outcome. The maximization of EU occurs at the operating point where a rational radiologist should make a clinical decision 24 . In this study, we aim to develop a decision framework by employing utility analysis to induce sensitivity and specificity, which allows us accurately assess prediction models in radiogenomics.
MATERIALS and METHODS

Subjects
We used data from a retrospective case-control study from Marshfield Clinic's Personalized Medicine Research Project (PMRP) 25 . Women of western European heritage with a plasma sample available, a mammogram, and a breast biopsy within 12 months after the mammogram were included. Subjects who have no mammography reports were excluded from the study. Subjects who have BRCA1 or BRCA2 mutations were also excluded. Cases were defined as women having a confirmed diagnosis of breast cancer obtained from the institutional cancer registry. In our case cohort, we included both invasive breast cancer and ductal carcinoma in situ. Controls were confirmed through the electronic medical records (and absence from the cancer registry) as never having had a breast cancer diagnosis. We employed an age matching strategy, selecting a control whose age was within five years of the age of each case in order to ensure similarity in age distribution in the case and control cohorts. We succeeded in identifying 373 cases and 395 controls. The age range for these subjects was 29 to 90 years of age (mean = 62, standard deviation = 12.8). 
Risk variables
For each subject, we collected Gail risk factors: age (at biopsy), age at menarche, number of previous biopsies, and family history of breast cancer (Table 1) . Age at first live birth was not available in our cohort so parity (number of pregnancies) was instead used in our prediction models because of its known association with breast cancer risk and correlation with age at first birth 26 . For genetic variants, we collected 10 commonly used single nucleotide polymorphisms (SNPs) in line with prior studies 27, 28 . We focused on high-frequency/low-penetrance genes that affect breast cancer risk (minor allele frequency >25%) as opposed to low frequency genes with high penetrance (BRCA1 and BRCA2) or intermediate penetrance (CHEK-2). For each SNP, we quantified how many risky alleles were present (0, 1, or 2 risky alleles) as the value. For mammography findings described in Breast Imaging-Reporting and Data System (BI-RADS) lexicon 29 , we collected 5 most informative mammographic features 14 ( Table 1 ).
Utility based decision framework
We first constructed three logistic regression models built on different sets of predictive features: (1) Gail, (2) Gail + SNP, and (3) Gail + SNP + BI-RADS. We generated receiver operator characteristic (ROC) curves using ROCKIT software 30, 31 based on the probabilities of malignancy predicted by each of the three models.
Then, we assigned utility values for each category of findings (True Negative (TN), False Positive (FP), False Negative (FN) and True Positive (TP)) as follows.
• We chose TN outcomes as our baseline and assigned a utility of zero.
• We assigned a loss of 4.7 days to the utility of FP, U FP based on the literature 32, 33 .
• We used the University of Wisconsin Breast Cancer Simulation (UWBCS) model 34 to estimate the utility of FN as a loss of 2.52 years 35 , •For TP, we assumed that its utility was U FN × (1-α), 0 ≤α≤1, where α is an unknown parameter representing the overall effectiveness of breast cancer treatment. In this study, we chose α as 0.86, the five-year survival rate from Surveillance Epidemiology and End Results (SEER) 36 program for breast cancer.
The expected utility of a prediction model f is defined as follows.
where E[ ] is the expected value of U(f). FPR (false positive rate) and TPR (true positive rate) are the coordinates of a point in ROC space for a given threshold level and p is the prevalence of breast cancer. We considered p to be fixed with typical value of 4 breast cancers per 1000 women screened 37 . The maximum expected utility (MEU) is defined as expected utility at the optimal operating point where the line with slope S is tangent to the ROC curve.
We pursued finding optimal operating points on ROC curves to achieve the maximum expected utility of breast cancer diagnosis. We obtained sensitivity, specificity, and threshold level at the optimal operating point. McNemar's test was used to evaluate the difference of predictive performance for the three models, demonstrating the effects of SNPs and mammographic features in breast cancer risk estimation. For the Gail model, the threshold at the optimal operating point was 0.644 when MEU was achieved, its sensitivity was 0.147, and its specificity was 0.912. When SNPs were added for risk prediction, at the optimal threshold of 0.659, the sensitivity of Gail + SNP model improved to 0.276 while its specificity decreased to 0.855. When additional mammographic features were added, the sensitivity of Gail + SNP + BI-RADS model improved to 0.457 and its specificity became 0.870 at the optimal threshold level of 0.643 (Figure 3 ). With threshold levels at the optimal operating points, subjects could be reclassified according to their risk of breast cancer (Table 2 & 3) . Using McNemar's test, we found that SNPs and mammographic features played a significant role in breast cancer risk estimation (p-value < 0.001). For this case/control study, when SNPs were added to the Gail model, 59 subjects were upgraded to high risk. Similarly, when both SNPs and BI-RADS features were added to the Gail model, 121 subjects were upgraded. 
RESULTS
We found that
DISCUSSION
We have developed a novel decision framework combining utility analysis and McNemar's test to efficiently evaluate prediction models in the new discipline of radiogenomics. Specifically, we determine threshold levels at optimal operating points to measure the performance of breast cancer prediction models in terms of sensitivity and specificity. Understanding optimal operating points from a decision analytic standpoint creates the opportunity for developing prediction models to look for novel and effective biomarkers in clinical practice to ultimately improve care.
achieve two important goals in breast cancer risk prediction. The first goal is to identify effective biomarkers. In order to use risk factors in predictive models effectively, it is necessary to quantify the value of these risk factors and select important variables when a large amount of risk factors available. In breast cancer risk prediction, accuracy is a high priority and efficiency is an important second goal. Identifying important variables may help improve the efficiency of breast cancer risk interpretation directly in order to enable physicians to focus on the most important features. The other goal is to specify optimal operating points in decision making, since a radiologist consciously or subconsciously chooses one threshold point for recommending operation. There are a lot of methods to identify the optimal operating points. However, most of them are short of a theoretical foundation 38 . Utility analysis in our framework leads us to identify optimal operating points by considering different clinical outcomes with scientific justification.
Expected utility analysis leverages ROC analysis by explicitly considering the clinical consequences of decisions. However, EU analysis has received relatively little attention in practical settings because it requires the agreement upon the utility of each outcome. There are two potential approaches to expected utility analysis. One is to specify the utility of each outcome directly and implement the analysis. The other is to define a ratio of utilities and to estimate the ratio from clinical studies that involve patient management [39] [40] [41] . In this study, we follow the first approach to implement utility analysis by specifying the utilities of outcomes based on a simulation model and the literature, which demonstrates that it is very promising to use utility analysis to evaluate prediction models even though the challenges of utility specification exist.
The ongoing discovery of new risk factors presents opportunities and challenges for researchers to evaluate these risk factors and incorporate them into prediction models. In genetics studies, each SNP is expected to contribute a small amount to the capability of prediction models. Many more SNPs with this low-level information will need to be discovered to substantially improve risk prediction 21 . Prior studies have identified the challenges of using AUC to evaluate the added predictive ability of a new biomarker, and proposed net reclassification improvement (NRI) analysis to assess the improvement in mode performance offered by a new biomarker 22, 23, 42 . NRI analysis would accurately capture the low utility of a biomarker in the new discipline of radiogenomics but it treats each outcome equally. However, it is rare that different outcomes have the same effect on a patients' quality of life in clinic. Our framework improves NRI analysis by considering the utility of each possible outcome explicitly to specify an optimal operating point. We determine threshold levels at optimal operating points to measure the performance of breast cancer prediction models in terms of sensitivity and specificity.
There are several limitations to our study. First, the sample size is small compared with large-scale genomewide association studies, due to the inherent difficulty of collecting a rich multi-modality dataset. Second, our study used logistic regression models to estimate breast cancer risk. A possible line of future research is to employ other prediction models such as Bayesian network, artificial neural network, or support vector machine for validating our results. Third, we obtained the utility of false positive from the literature and the utility of true positive from domain knowledge. We plan to use UWBCS model to obtain both utilities. Finally, we need to validate our decision framework using other study populations.
CONCLUSIONS
Genetic variants and mammographic features have the potential to lead to substantial improvements in breast cancer risk prediction. In addition, our proposed decision framework could be used as a general technique to characterize optimal thresholds and to quantify potential predictive power of different imaging modalities and biomarkers.
